GlassScriptPhysician profile
Lorraine M Calvert
NPI 1730166778
$7,738.32
in general payments reported to CMS, 2019-2025
48 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $1,345 · 2023: $2,302 · 2024: $1,794 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,216.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,005.53 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $839.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $511.40 | 2022-2025 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $503.19 | 2022-2024 | Korlym |
| Medtronic, INC. | $381.61 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Radius Health, INC. | $334.62 | 2022-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $278.54 | 2022-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $277.79 | 2022-2025 | |
| Abbott Laboratories | $266.85 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Novartis Pharmaceuticals Corporation | $260.23 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $252.88 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $245.39 | 2022-2025 | |
| Novo Nordisk INC | $236.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $196.41 | 2022-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $188.71 | 2022-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $180.55 | 2022-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $161.14 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $158.96 | 2022-2025 | Afrezza |
| Astellas Pharma US INC | $126.58 | 2024-2025 | Veozah |
| Recordati_rare_diseases_inc. | $115.27 | 2023-2025 | Isturisa |
| Beta Bionics, INC. | $104.30 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals LP | $103.39 | 2022-2023 | Farxiga |
| Sequel Med Tech, LLC | $89.54 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.26 | 2023-2025 | Jardiance |
| Ibsa Pharma INC. | $85.98 | 2022-2025 | Tirosint, Licart, Tirosint |
| Ascendis Pharma Endocrinology INC | $69.93 | 2023-2025 | Yorvipath |
| Kyowa Kirin, INC. | $66.56 | 2023-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $60.87 | 2022-2023 | |
| Madrigal Pharmaceuticals | $58.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Amryt Pharma Holdings LTD | $52.86 | 2023 | Mycapssa |
| Alnylam Pharmaceuticals INC. | $52.43 | 2023 | Onpattro |
| Neurocrine Biosciences, INC. | $49.63 | 2025 | |
| Lifescan, INC. | $42.60 | 2022-2023 | |
| Horizon Therapeutics Plc | $33.91 | 2023 | Tepezza |
| Kowa Pharmaceuticals America, INC. | $26.53 | 2023 | Livalo, Seglentis |
| Amarin Pharma, INC. | $24.91 | 2022 | |
| Averitas Pharma INC. | $23.31 | 2023 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $22.13 | 2022 | |
| Halozyme INC | $19.99 | 2023 | |
| Chiesi USA, INC. | $19.62 | 2025 | Mycapssa |
| Antares Pharma, INC. | $18.27 | 2022 | |
| Cequr Corporation | $17.40 | 2023 | Cequr Simplicity |
| Almatica Pharma LLC | $15.77 | 2024 | Teriparatide, Loreev Xr |
| Vivus LLC | $15.52 | 2022 | |
| Merck Sharp & Dohme LLC | $15.19 | 2022 | |
| Esperion Therapeutics, INC. | $14.56 | 2025 | Nexletol |
| Acella Pharmaceuticals, LLC | $12.84 | 2023 | NP Thyroid 60 |
| Acerus Pharmaceuticals Corporation | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Calvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.